Eli Lilly and Company will invest $ 850 million for expansion of its US operations - spanning facilities across its US enterprise, including research laboratories, manufacturing sites, and general and administrative areas - in 2017. The investments are being driven by demand for Lilly products, as well as its robust pipeline of potential medicines in development targeting cancer, pain, diabetes and other unmet medical needs.
Company leaders were joined by federal, state and local government officials at Lilly Technology Center on March 24, 2017, where the details of the investments were unveiled, including plans for a new $ 85 million expansion